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This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the
tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The primary study end
point was objective response according to RECIST, secondary end points were safety, overall and progression-free survival. In all, 18
patients with treatment-refractory advanced melanoma received imatinib 800mgday
 1. In 16 evaluable patients no objective
responses could be observed. The median overall survival was 3.9 months, the median time to progression was 1.9 months. Tumour
biopsy specimens were obtained from 12 patients prior to imatinib therapy and analysed for c-kit, PDGF-Ra and -Rb expression by
immunohistochemistry. In four cases, cell lines established from these tumour specimens were tested for the antiproliferative effects
of imatinib and for functional mutations of genes encoding the imatinib target molecules. The tumour specimens stained positive for
CD117/c-kit in nine out of 12 cases (75%), for PDGF-Ra in seven out of 12 cases (58%) and for PDGF-Rb in eight out of 12 cases
(67%). The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in
the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect. In conclusion,
this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib
target molecules c-kit and PDGF-R.
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At present, no treatment options are available for melanoma
patients with advanced metastastic disease that provide either
sufficient response rates or a significant prolongation of overall
survival (Eigentler et al, 2003; Ugurel and Schadendorf, 2003).
Thus, despite all therapeutic efforts, the 5-year-survival rate in
melanoma patients with metastases to the subcutis and distant
lymph nodes is less than 20% (Balch et al, 2001), in patients with
metastases to the lung and other organs it ranges between 6.7 and
9.5% (Balch et al, 2001). Chemotherapy with dacarbacine (DTIC)
does actually apply as the standard treatment regimen in advanced
melanoma, leading to response rates between 9.9 and 18% (Crosby
et al, 2001). Polychemotherapy as well as therapy regimens
combining cytostatics with cytokines do not add any substantial
survival benefit to DTIC monotherapy (Crosby et al, 2001;
Eigentler et al, 2003).
Due to this unfavourable situation, recent approaches to gain a
stronger efficacy against melanoma focused on new target-directed
therapeutic strategies. Here, in particular, signalling pathways and
their key molecules, such as bcl-2 (Jansen et al, 2000) or Ras-Raf-
MAPK (Collisson et al, 2003; Sumimoto et al, 2004), became
targets of interest. A group of signal transductory molecules of
crucial importance for the regulation of cell growth and survival
are the receptor tyrosine kinases. A small therapeutic molecule
designed to selectively inhibit these kinases is imatinib mesylate
(Glivec
s, formerly STI571, Novartis, Basel, Switzerland). Imatinib
selectively binds to the tyrosine kinases Abl and Kit, as well as the
platelet-derived growth factor receptors (PDGF-R) alpha and beta.
Due to its mechanisms of action, imatinib has been used
successfully in chronic myelogenous leukaemia (CML) (Druker
et al, 2001) and in gastrointestinal stromal tumours (GIST) (van
Oosterom et al, 2001).
Melanoma cells are known to express c-kit, PDGF-R and Abl
(Worm et al, 1993; Montone et al, 1997; Welker et al, 2000; Potti
et al, 2003; Shen et al, 2003). Moreover, based on experimental in
vitro data gained from melanoma cell lines, autocrine growth loop
mechanisms were postulated for the receptor–ligand interaction of
PDGF-R and PDGF, as well as of Kit and stem cell factor (SCF)
(Harsh et al, 1990; DiPaola et al, 1997). Thus, by inhibiting cell
viability and proliferation via inhibition of receptor tyrosine
kinases, imatinib might be a successful therapeutic in malignant
melanoma. A first study investigating the growth behaviour of two
human melanoma cell lines in athymic nude mice showed that
imatinib treatment of these mice resulted in an inhibition of
PDGF-R phosphorylation but no decrease in tumour size (McGary
et al, 2004). In contrast, a recent report on murine B16F10
melanoma cells injected into C57B16 mice revealed a strong and
efficient tumour growth inhibition by imatinib (Redondo et al,
2004). The same study also demonstrated a growth inhibition
effect of imatinib on B16F10 melanoma cells in vitro.
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efficacy of imatinib in patients with advanced metastatic
melanoma in correlation to the tumour expression profile of its
target molecules c-kit and PDGF-R.
PATIENTS AND METHODS
Study design
This study was designed as a two-centre prospective open-label
phase-II trial to investigate the safety and efficacy of imatinib in
treatment-refractory metastatic malignant melanoma. The primary
study end point was objective response, secondary end points were
overall survival, time to progression and toxicity. All end points
were evaluated on an intention-to-treat (ITT) and on a per
protocol (PP) basis. Toxicity was analysed in all patients who
received study treatment.
Patient population
Patients with histologically confirmed metastastic melanoma were
enrolled into the study in accordance with the following eligibility
criteria: melanoma disease refractory to at least one previous
treatment regimen; at least one measurable target lesion following
the response evaluation criteria in solid tumours (RECIST)
(Therasse et al, 2000); no brain metastases; ECOG performance
status p2; age above 18 years; adequate bone marrow function
(leukocytes X3000ml
 1, platelets X100000ml
 1); and satisfactory
hepatic and renal functions. Patients with severe and/or uncon-
trolled medical diseases other than melanoma were excluded from
the study. The study protocol was approved by the Institutional
Review Boards of the participating centres and a written informed
consent was signed by all patients prior to enrolment.
Cells and tissues
Biopsy specimens from metastatic lesions were taken from 12
patients prior to the onset of study treatment with written
informed consent. Specimens were divided into two parts, with
one being subsequently embedded into paraffin and the other used
for cell culture. For cell culture purposes, the biopsy specimens
were minced and thereafter maintained in RPMI 1640 (Life
Technologies, Grand Island, NY, USA) supplemented with 10%
foetal calf serum (Life Technologies), 5mML-glutamine, 100Uml
 1
penicillin and 100mgml
 1 streptomycin at 371C in a humidified
5% CO2 atmosphere. Established cell lines were used for further
investigations no earlier as after six to eight passages.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded 5mm tissue sections were
pretreated with 0.1% protease type XIV (P-5147, Sigma-Aldrich,
Munich, Germany) for 10min at 371C prior to the incubation with
primary antibodies. The following primary antibodies were used:
anti-CD117/c-kit (rabbit polyclonal IgG A4502, DakoCytomation,
Glostrup, Denmark), anti-PDGF-Ra (rabbit polyclonal IgG #07-
276, Upstate, Lake Placid, NY, USA) and anti-PDGF-Rb (rabbit
polyclonal IgG #06-498, Upstate). The tissue sections were
incubated with the primary antibodies diluted 1:100 for 1h at
room temperature. After several washes, the bound primary
antibodies were visualised using streptavidin–biotin labelling
(LSAB-kit, DakoCytomation) according to the manufacturer’s
instructions. The resulting immunostaining appears in red colour;
nuclei were counterstained with haematoxylin (blue colour). In
each case, negative controls were performed by substituting the
primary antibodies by irrelevant IgG antibodies. The intensity of
immunostaining was graded as negative ( ), weak (þ), moderate
(þþ) or strong (þþþ). Melanomas with weak to strong
staining in more than 10% of the tumour cells were considered as
positive.
The melanoma cell lines were allowed to grow to confluence.
After gentle detachment by incubation with 0.05% EDTA/PBS
for 10min, the cells were centrifuged at 1500g for 5min.
The obtained cytospin preparations were fixed with 2% parafor-
maldehyde, air-dried, and subsequently pretreated with 0.1%
protease type XIV for 10min at 371C. Thereafter, the specimens
were incubated with the above-mentioned primary antibodies
at a concentration of 1:100 overnight (ckit and PDGF-Ra) and
for 1h (PDGF-Rb) at room temperature. After several washes, the
bound primary antibodies were visualised using streptavidin–
biotin labelling. The resulting immunostaining appears in red
colour; nuclei were counterstained in blue with haematoxylin.
Negative controls were performed by substituting the primary
antibodies by irrelevant IgG antibodies. The intensity of immu-
nostaining was graded as negative ( ), weak (þ), and moderate to
strong (þþ).
Mutation analysis
RNA from melanoma cell lines was extracted by CsCl gradient
centrifugation as described previously (Cross et al, 1993). RNA was
transcribed into copy DNA (cDNA) using random hexamer
primers and Moloney murine leukaemia virus reverse transcrip-
tase. The sequences of the primers used for PCR amplification of
the entire c-kit coding region are published elsewhere (Longley
et al, 1999). In all, 3ml of cDNA was amplified for 31 cycles of 1min
at 941C, 1min at 581C and 1min at 721Ci n5 0ml containing 1mM
primers, 1.8mM MgCl2, 0.2mM each of all four dNTPs, 20mM Tris-
HCl (pH 8.4), 50mM KCl and 1.5U of Taq polymerase. Specific
primers were designed to amplify the transmembrane, juxtamem-
brane and kinase regions of PDGF-Ra and -Rb (Table 1). The PCRs
were performed in a final volume of 25ml containing 0.8mM
primers, 1.8mM MgCl2, 0.24mM each of all four dNTPs, 20mM
Tris-HCl (pH 8.4), 50mM KCl, 4ml of cDNA and 1.5U of Taq
polymerase. The thermal profile of 35 amplification cycles was:
941C for 50s, 621C for 45s, followed by 721C for 1min. PCR
products were visualised on 1.5% agarose gels stained with
ethidium bromide. The products were sequenced and checked
for mutations by comparison with reference databases
(NM_000222 for c-kit, NM_006206 for PDGF-Ra, NM_002609 for
PDGF-Rb).
Cytotoxicity assay
To test the cytotoxic effect of imatinib on melanoma cell lines in
vitro, MTS assays (Mosmann, 1983) were performed using the
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit
(Promega, Mannheim, Germany) following the manufacturer’s
instructions. The imatinib-sensitive, Bcr–Abl-positive CML cell
line Lama84 (Deininger et al, 1997) was used as a control. The cells
were plated into 96-well microtitre plates in quadruplicate at a
concentration of 5 10
3cellswell
 1 and exposed to escalating
doses of imatinib ranging from 0 to 10mM. These doses were
selected according to a predescribed range of clinical relevance
(Peng et al, 2004), with a maximum of 10mM being beyond clinical
feasibility. After 72h of incubation, the colour reaction was
performed and subsequently recorded at 490nm using an ELISA
plate reader. The inhibition of cell growth under exposure with
imatinib was calculated as the percentage of cell growth with
medium alone.
Treatment plan
The study treatment regimen was imatinib (Glivec
s, Novartis,
Basel, Switzerland) 400mg p.o. bid (800mg daily) for 8 weeks.
Thereafter, treatment was continued at a tumour response of stable
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disease progression or intolerable side effects. Recommended
concomitant medications were metoclopramide in case of nausea
and loperamide in case of diarrhoea, if required. Toxicity was
evaluated using common toxicity criteria (CTC) (http://ctep.can-
cer.gov/reporting/ctc.html) and assessed at weekly intervals within
the first 4 weeks of therapy, followed by 2-week intervals
thereafter. Imatinib doses were adjusted due to toxicities as
described previously (Demetri et al, 2002). After completion of
study treatment, the patients were followed in at least 2 months
intervals for the first 6 months and at least every 3 months
afterwards.
Response and survival assessment
Patients who completed at least 1 week of study treatment were
considered evaluable for response. Tumour response was assessed
by CT and/or MRI imaging in 8-week intervals and subsequently
evaluated according to the RECIST guidelines (Therasse et al,
2000). Best response was defined as the best tumour response
recorded from the start of treatment until removal of the patient
from the trial. Overall survival and time to progression were
measured from onset of study treatment until death or disease
progression, respectively. If no such event occurred, the date of the
last patient contact was used as the end point of OS or TTP
assessment (censored observation).
Statistical analysis
Patient recruitment was outlined as a total of 30 patients evaluable
for objective response. A first interims analysis of imatinib efficacy
was performed after the enrolment of 16 evaluable patients. Since
no objective response could be achieved in this patient cohort,
recruitment into the study was stopped at that time point, with a
current number of 18 patients enrolled.
Survival curves were calculated and graphically presented using
the Kaplan–Meier method for censored failure time data. The
database was frozen on June 30, 2004. Statistical analyses were
performed using the statistical packages ADAM of the Biostatistics
Unit of the German Cancer Research Center and SAS for Windows
Version 8.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics and study flow
Between April 2002 and February 2003, 18 patients (ITT) with a
median age of 54.2 years (range 38.9–72.0 years) were recruited
into the study from two centres, Mannheim (15 patients) and
Wuerzburg (three patients) (Figure 1). The prognostic indices of
the study cohort at the time of enrolment were poor: 12 out of 18
patients (67%) presented with an ECOG performance score 40, 16
out of 18 (88%) were staged as AJCC M1c, and 10 out of 18 (56%)
had progressed under two or more previous therapy regimens.
Detailed patient characteristics are provided in Table 2.
In all, 12 biopsy specimens from metastatic lesions were
obtained from 12 different study patients prior to the onset of
imatinib treatment. Detailed information about the specimens’
origin is provided in Table 3. Melanoma cell lines (Ma-Mel-46, Ma-
Mel-52, Ma-Mel-54a, Ma-Mel-59a) could be established from four
of these specimens (Table 4).
Table 1 Primer sequences for amplification of PDGF-Ra and -Rb
Primer pair Oligonucleotide sequence (50–30) Position
a
PDGF-Ra 1
Forward ATC TCC TTG GAG CTG AGA ACC G 1653–1674
Reverse AAG ACC CGA CCA AGC ACT AGT C 1935–1914
PDGF-Ra 2
Forward CGA TGC AGC TGC CTT ATG ACT C 1869–1890
Reverse ACA TAG CTC CGT GTG CTT TCA TC 2301–2279
PDGF-Ra 3
Forward AAG TCA GGC CCC ATT TAC ATC A 2135–2156
Reverse GTC CCA GGA GGA CGT TGC 2621–2604
PDGF-Ra 4
Forward AGA TGA TAA CTC AGA AGG CCT TAC 2488–2511
Reverse TCA CTG GTA GCG TGG TCA GGC 2910–2890
PDGF-Ra 5
Forward CGG CAT GAT GGT GGA TTC TAC T 2830–2851
Reverse CTC TTC AGA GGT CTG CGA GCT G 3280–3259
PDGF-Ra 6
Forward GTA CCT TTC TGC CCG TGA AG 2700–2719
Reverse GGA AGG AAC CCC TCG AAT CC 3434–3415
PDGF-Rb 1
Forward ACG CAG GAG GTC ATC GTG GTG 1908–1928
Reverse TTG TTG CGG TGC AGG TAG TC 2446–2427
PDGF-Rb 2
Forward ATT CTC AGG CCA CGA TGA A 2227–2245
Reverse GGG CAG AGG GAA CGT AGT TAT 2703–2683
PDGF-Rb 3
Forward CCA ACT ACA TGG CCC CTT ACG 2662–2682
Reverse TTT TGT AAC CTT CGC CCA ACA 3258–3238
PDGF-Rb 4
Forward GAC TGT TGG GCG AAG GTT ACA 3235–3255
Reverse CAG TGG GCC CTC GTC AGC 3470–3453
PDGF-Rb 5
Forward GGG TTC CAT GGC CTC CGA TCT 3336–3356
Reverse GTT TGG GGC ACA ACA CGT CAG 3832–3812
aNucleotide positions are shown according to the PDGF-Ra and -Rb coding
sequences, accession NM_006206 and NM_002609, respectively.
Enrolled: n = 18 pts
Received imatinib:
n = 18 pts
< 7 days:   n = 2 pts
7 – 14 days:   n = 2 pts
15 – 28 days:  n = 3 pts
29 – 56 days:  n = 2 pts
57 – 84 days:  n = 8 pts
>84 days:   n = 1 pt
Evaluation of response
and survival:
n = 16 pts
Excluded from evaluation
(n = 2 pts) due to less than 7 
days of study treatment
Tumour
specimens
(n = 12 pts)
ITT (n = 18)
PP (n = 16)
Tumour
cell lines
(n = 4 pts)
Figure 1 Schematic presentation of the study flow. For further details,
see Table 2.
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sTable 2 Patient characteristics
ITT population 18 (100.0%)
Sex
Male 11 (61%)
Female 7 (39%)
Median age (years) 54.2 (Range 38.9–72.0)
LDH
pUNL 5 (28%)
4UNL 13 (72%)
Performance status (ECOG)
0 6 (33%)
1 9 (50%)
2 3 (17%)
Metastatic sites
a
Skin/lymph nodes 18 (100%)
Lung 11 (61%)
Liver 5 (28%)
Other visceral 6 (33%)
Bone 1 (6%)
M category (AJCC)
M1a 1 (6%)
M1b 1 (6%)
M1c 16 (88%)
Pretreatment (in stage IV)
a
Chemotherapy 18 (100%)
Immunotherapy 11 (61%)
1 therapy regimen 8 (44%)
2 therapy regimens 8 (44%)
X3 therapy regimens 2 (12%)
PP population
b 16
aMultiple entries possible.
bReasons for exclusion from evaluation see study flow
(Figure 1). ITT, intention to treat; LDH, lactate dehydrogenase; UNL, upper normal
limit; ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint
Committee on Cancer; PP, per protocol.
Table 3 Immunohistochemical analysis
Tissue specimen 12 (100%)
Origin of specimen
Subcutaneous met 8 (66%)
Lymph node met 2 (17%)
Liver met 2 (17%)
CD117/c-kit
+++ 1 (8%)
++ 2 (17%)
+ 6 (50%)
  2 (17%)
ND 1 (8%)
PDGF-Ra
+++ 0 (0%)
++ 0 (0%)
+ 7 (58%)
  5 (42%)
PDGF-Rb
+++ 1 (8%)
++ 0 (0%)
+ 7 (58%)
  4 (34%)
Biopsies were obtained from metastatic lesions of 12 study patients prior to the onset
of imatinib therapy. Processing of tissue specimens, see Patients and Methods. The
staining intensity of melanoma cells was graded as follows: +++, strong; ++,
moderate; +, weak;  , negative. Met, metastasis; ND, not done.
Table 4 Tyrosine kinase expression pattern in melanoma tissues and
corresponding cell lines
Patient #02 Patient #05 Patient #16 Patient #18
Female Male Female Male
51 years 62 years 41 years 52 years
Tissue
Origin Subcutaneous Subcutaneous Lymph node Lymph node
Immunohistochemistry
CD117/c-kit ++ +++ + ++
PDGF-Ra +   ++
PDGF-Rb ++  
Cell line
Name Ma-Mel-46 Ma-Mel-52 Ma-Mel-54a Ma-Mel-59a
Immunohistochemistry
CD117/c-kit +   ++  
PDGF-Ra    ++ ++
PDGF-Rb ++   +  
RT–PCR
CD117/c-kit + + + (+)
PDGF-Ra ++++
PDGF-Rb ++++
Patient’s clinical outcome
Overall survival (days) 88 7 20 74
Expression of tyrosine kinases was measured in melanoma tissue samples and
corresponding cell lines as described in Patients and Methods. The patients are
numbered according to the time point of inclusion into the study.
CD117/c-kit
PDGF-R
PDGF-R
pos neg
+++
+
+
−
−
−
Figure 2 Immunohistochemical staining of CD117/c-kit, PDGF-Ra and
PDGF-Rb in biopsy specimens of metastatic lesions obtained from six
different melanoma patients prior to imatinib treatment. One representa-
tive example of each, positive and negative staining, is presented.
Magnification  100.
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The paraffin-embedded sections derived from metastatic tissue
specimen were reviewed by one of the authors (RH). The clinical
diagnosis of melanoma metastasis could be verified in all 12 cases.
Immunohistochemical staining revealed a positivity of the
melanoma cells for CD117/c-kit in nine out of 12 cases (75%),
for PDGF-Ra in seven out of 12 cases (58%) and for PDGF-Rb in
eight out of 12 cases (67%). Representative cases of positive and
negative staining results are provided in Figure 2. Detailed staining
characteristics are given in Table 3.
Staining of the cytospin preparations of the four patient-derived
melanoma cell lines showed two cell lines (Ma-Mel-46 and
Ma-Mel-54a) expressing almost all of the three receptor
tyrosine kinases tested in a weak to strong pattern (besides
Ma-Mel-46 staining negative for PDGF-Ra), whereas the other
two cell lines (Ma-Mel 52 and Ma-Mel-59a) were nearly negative
for those molecules (besides Ma-Mel-59a staining positive for
PDGF-Ra) (Table 4; Figure 3). Staining discrepancies were
observed between the tissue samples and the corresponding cell
lines (Table 4).
Mutation analysis of c-kit, PDGF-Ra and -Rb
Sequencing of the entire c-kit coding region was performed
successfully in three melanoma cell lines (Ma-Mel-46, Ma-Mel-52
and Ma-Mel-54a). The cell line Ma-Mel-59a showed only a
weak expression of c-kit at the RNA level, not allowing a
reliable sequencing of the PCR products. No mutations or base
variants were found in any of the analysed c-kit sequences. In
all four cell lines, the regions encoding for the transmembrane,
juxtamembrane and kinase domains of PDGF-Ra and -Rb were
analysed. The obtained nucleotide sequences revealed base
changes and known polymorphisms that do not alternate the
amino-acid sequence.
In vitro cytotoxicity
As shown in Figure 4, none of the four cell lines tested showed a
significant growth inhibition at imatinib concentrations up to
10mM. In contrast, Bcr–Abl-positive Lama84 cells were inhibited
with an IC50 of approximately 62.5nM, confirming the selective
activity of imatinib in Bcr–Abl-positive CML cells.
Treatment-related toxicity
Common toxicity criteria grade 3 or 4 treatment-related toxicities,
as well as all toxicities leading to a dose modification of imatinib,
are summarised in Table 5. Grade 3 or 4 toxicities were
experienced by five patients (27.8%); dose modifications of
imatinib became necessary in seven patients (38.9%). Three
patients (16.7%) discontinued study treatment due to severe
adverse events (intestinal perforation, arterial thromboembolism,
suicide attempt). In one case (intestinal perforation) the severe
adverse event led to a fatal outcome.
CD117/c-kit
PDGF-R
PDGF-R
Control IgG
Ma-Mel-46 Ma-Mel-52 Ma-Mel-54a Ma-Mel-59a
+
++
++ ++
++
+
−−
− −
− −
Figure 3 Immunohistochemical staining of CD117/c-kit, PDGF-Ra and PDGF-Rb in cytospin specimens of four patient-derived melanoma cell lines.
Staining with irrelevant control IgG served as control. Magnification  200.
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All 18 patients enrolled into the study (ITT population) received study
treatment; the treatment durations are presented in Figure 1. Two
patients had to be excluded from the PP evaluation due to a treatment
duration of less than 1 week, leading to a total number of 16 patients
evaluable for response and survival (PP population; Figure 1). In one
of these two patients treatment was stopped prematurely due to a
severe adverse event (intestinal perforation). The other patient
excluded from PP analysis experienced a rapid disease progression
accompanied by a severe decline of overall performance, requiring a
discontinuation of imatinib after 5 days of treatment. In regard to the
PP population, no objective responses were observed. One patient
(6%) achieved a stabilisation of disease for 2.6 months, whereas the
remaining 15 patients (94%) experienced a tumour progression after
2–8 weeks. After disease progression, under imatinib, five patients
(31%) were treated with other therapeutic regimens. One of these
latter patients achieved a complete remission after radical surgery,
which is still ongoing (15þ months).
Survival analysis
At the time of data analysis (July 2004), the median follow-up time
was 18.9 months and a total number of 16 deaths had occurred, all
of them due to melanoma disease. The ITT population revealed
a median overall survival of 3.9 months, with a 95% confidence
interval (CI) of 2.8–5.3 months; the median time to progression
was 1.9 months (95% CI 1.2–2.1 months). With regard to the
PP population, the median overall survival was 4.2 months
(95% CI 3.2–5.5 months); the median time to progression was
1.9 months (95% CI 1.6–2.2 months). The two patients who are
still alive are now surviving 19þ and 25þ months after onset of
imatinib treatment, respectively. No obvious correlation could be
observed between the tyrosine kinase expression pattern measured
by immunohistochemistry and the overall survival time of the
patients. However, it should be noticed that both of the patients
who are still alive stained positive for all three kinases, CD117/c-
kit, PDGF-Ra and -Rb, by immunohistochemistry.
DISCUSSION
The present study did not reveal any objective efficacy of imatinib in
advanced metastastic melanoma. The proof of concept failed to
show that melanoma cells expressing relevant amounts of the
receptor tyrosine kinases c-kit and PDGF-R can be inhibited in their
proliferative activity by imatinib in vitro and in vivo.T h e
immunohistochemical workup of the tumour material gained from
12 study patients prior to the onset of imatinib treatment revealed a
heterogenous protein expression pattern of the target receptor
kinases. Thus, the assumed direct impact of the receptor expression
pattern on the efficacy of imatinib treatment should have been
visible by differences in tumour response or survival between
receptor-positive and receptor-negative patients. No such differ-
ences were observed in this study. Additionally, tumour cell lines
were established from tumour specimens of four study patients.
Characterisation of these cell lines by immunohistochemistry
revealed that, from completely negative expression patterns of the
three receptor tyrosine kinases to completely positive patterns, all
kinds of combinations were represented. Despite these heterogenous
expression profiles, all melanoma cell lines tested negative for an in
vitro antiproliferative effect of imatinib. No correlation between the
receptor expression profile and the in vitro growth inhibition by
imatinib could be detected. These results are in line with recently
published data about melanoma-bearing athymic nude mice treated
with imatinib without efficacy, regardless of whether the melanoma
cells expressed PDGF-R or c-kit (McGary et al,2 0 0 4 ) .
Similar results were recently reported from a clinical trial
investigating imatinib as first- or second-line treatment in small
cell lung cancer (SCLC) (Johnson et al, 2003). In all, 19 patients
were included into this study, with 14 of them confirmed to have
SCLC. No objective responses could be observed. One patient
experienced a stabilisation of his disease. Only 21% of the study
patients showed a CD117/c-kit expression on the tumour speci-
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Figure 4 Growth inhibition by imatinib on four patient-derived
melanoma cell lines (Ma-Mel-46, Ma-Mel-52, Ma-Mel-54a, Ma-Mel-59a)
and one CML cell line (Lama84). Data are represented as cell growth
inhibition after 72h of imatinib exposure as percentage of growth after
incubation with medium alone. The depicted data points are means
generated from three independent experiments, each assayed in quad-
ruplicates.
Table 5 Treatment-related toxicity and dose modification
Sex (years of age) CTC
a grade 1–2 CTC grade 3 CTC grade 4 Dose modification (%)
b
m (42) Headaches, nausea, fatigue  25
m (71) Nausea, gum bleeding  25
f (41) Exanthema  50
f (51) Exanthema  50
m (62) Constipation Intestinal perforation  100
m (67) Arterial thromboembolism  100
m (61) Suicide attempt  100
aToxicity was graded according to common toxicity criteria (CTC; http://ctep.cancer.gov/reporting/ctc.html).
bModification of imatinib dose in terms of reduction of the initial
dose of 400mg bid. A dose reduction of 100% represents complete cessation of study treatment.
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smens obtained. The authors therefore argued that their trial
remained inconclusive and further investigations on larger patient
cohorts should be done to verify or falsify an anticancer effect of
imatinib in SCLC.
It might be argued as one possible explanation for the observed
negative results of our study as well, that a positive target molecule
expression pattern was not necessary for a patient’s inclusion. The
majority of clinical trials testing a targeted therapy require the
proof of a positive expression of the target molecule on the
patient’s tumour cells prior to inclusion, like, for example, in
clinical trials testing trastuzumab in breast cancer (Vogel et al,
2002; Burstein et al, 2003). However, we found that 11 out of 12
(92%) of the tumour biopsies tested were positive for at least one
of the three target tyrosine kinases. Three out of 12 tumour
biopsies (25%) were positive for all three kinases; five out of 12
(42%) were positive for two of them; and three out of 12 (25%)
were positive for one. Only one biopsy specimen (8%) was
completely negative for all the three target molecules. Thus, the
frequency and pattern of expression of the target molecules can be
rated as sufficient for an investigation of the assumed antitumoral
activity of imatinib.
Recent studies investigating the tyrosine kinase inhibitor
gefitinib in non-small-cell lung cancer (NSCLC) showed that the
outcome of patients treated with targeted anticancer agents does
not necessarily correlate with the expression quality and quantity
of its target molecule, in this case epidermal growth factor receptor
(EGFR) (Parra et al, 2004). A recent study in colorectal cancer
patients revealed clinical efficacy of the EGFR inhibitory antibody
cetuximab in patients with immunohistochemical EGFR-negative
tumours (Chung et al, 2005). Moreover, it could be shown that
gefitinib in NSCLC exerts clinical efficacy in 10% of patients only,
and this efficacy was associated with specific activating mutations
in the EGFR gene (Lynch et al, 2004). In the light of these findings,
the number of 16 patients evaluable for tumour response and
survival in the present study might be too small to detect a
comparably low response rate.
Despite the high clinical efficacy of imatinib in CML and GIST, it
became evident that subgroups of patients do not respond to the
drug, or relapse after an initial response, respectively. The clinical
resistance to imatinib in CML is caused by two major mechanisms:
an amplification of the Bcr–Abl gene or mutations in the catalytic
domain of the protein (Gorre et al, 2001; Hochhaus et al, 2002;
Roumiantsev et al, 2002; Azam et al, 2003). In GIST, mutations of
kit or PDGF-R are made responsible for the observed resistance to
imatinib (Heinrich et al, 2003; Chen et al, 2004). Trying to exclude
mutations of the target receptor proteins in our study, we
sequenced the genes of c-kit, PDGF-Ra and -Rb in the melanoma
cell lines derived from the four study patients. We did not find any
gene mutations that would lead to a change in the amino-acid
sequence of the target molecules of interest. Nevertheless, gene
sequencing could be carried out in cell lines derived from four
patients only. Thus, we have no information about the mutation
status of the other 14 patients.
Imatinib is known as a highly efficient drug with low toxicities
(Druker et al, 2001). Thus, it seems noteworthy that we observed
an unexpectedly high rate of side effects in our present study. Five
out of 18 (28%) patients experienced CTC grade 3 or 4 toxicities,
one of them with a fatal outcome. Four patients developed strong
cutaneous adverse events, two of them CTC grade 3, that were
published previously (Ugurel et al, 2003). Dose modifications
became necessary in seven out of 18 patients (39%); in three out of
18 patients (17%) treatment had to be stopped completely. One
possible reason for this increased rate of side effects might be the
high dose of imatinib (800mgd
 1) used in this study. The
common dose range used in CML is 400–600mgday
 1. Since
melanoma is a solid tumour like GIST, the imatinib regimen of the
present study was chosen according to the dose that was used in
GIST at the time the present trial was designed, which was 400–
1000mgday
 1 (van Oosterom et al, 2001). Another possible
explanation for the high frequency of severe toxicities is the fact
that the patient population enrolled into our study according to
the inclusion criteria had extremely poor prognostic criteria with
high tumour burden, poor performance status and high numbers
of pretreatment regimens.
In conclusion, this first clinical trial of imatinib in melanoma
did not reveal an efficacy of imatinib as rescue treatment of
advanced metastatic patients. The expression profile of the target
molecules of imatinib on tumour samples obtained from the study
patients showed no impact on tumour response or overall survival.
Severe toxicities occurred more frequently than expected, leading
to dose modifications in 39% of the patients. However, assumed
that imatinib might be effective in a smaller subgroup of
melanoma patients only, the number of 16 patients evaluable for
response and survival in the present study is too small for a
negative proof of concept.
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